UBS’s Array Biopharma Inc ARRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$26K Sell
7,300
-6,800
-48% -$26.8K ﹤0.01% 7675
2014
Q2
$64K Buy
14,100
+4,100
+41% +$17K ﹤0.01% 6530
2014
Q1
$47K Buy
10,000
+8,600
+614% +$43.2K ﹤0.01% 6936
2013
Q4
$7K Sell
1,400
-4,200
-75% -$22.9K ﹤0.01% 9362
2013
Q3
$35K Sell
5,600
-200
-3% -$1.19K ﹤0.01% 7348
2013
Q2
$26K Buy
+5,800
New +$31.2K ﹤0.01% 7584

Other funds holding ARRY

UBS's ARRY Position: Q3 2014 in Review

UBS reduced its Array Biopharma Inc (ARRY) stake by 5.9% in Q3 2014, selling an estimated $16.1K and leaving 64,709 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #5049.

UBS first reported a position in ARRY in Q2 2013 and has held it in 6 quarters since. The position peaked at $331K in Q1 2014. 112 funds tracked by Wall St. Rank hold ARRY as of Q3 2014.

  • UBS held 64,709 shares of Array Biopharma Inc worth $231K as of Q3 2014.
  • UBS sold 4,083 Array Biopharma Inc shares in Q3 2014, an estimated $16.1K.
  • Array Biopharma Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5049 holding.
  • UBS first reported a position in Array Biopharma Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Array Biopharma Inc position peaked at $331K in Q1 2014.
  • 112 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.